Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020¶
Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., et al. (2020). Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Outbreak Underascertainment
- A CDC-led study of residual clinical blood specimens across ten U.S. sites (Havers et al., JAMA Internal Medicine, 2020) estimated that the number of people with SARS-CoV-2 antibodies exceeded reported cases by roughly 6- to 24-fold, the multiplier varying by site and period with local testing intensity
This sourceHavers et al. is the study the sentence names: residual specimens from 16,025 people at ten US sites, March-May 2020, with adjusted seroprevalence from 1.0% (San Francisco Bay) to 6.9% (New York City) and infections exceeding reported cases by 6- to 24-fold, seven sites above tenfold - a single estimate per site rather than a within-site trend.
- A CDC-led study of residual clinical blood specimens across ten U.S. sites (Havers et al., JAMA Internal Medicine, 2020) estimated that the number of people with SARS-CoV-2 antibodies exceeded reported cases by roughly 6- to 24-fold, the multiplier varying by site and period with local testing intensity
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:a11b5018f54f · see in the full table